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Typhoid fever, due to S. typhi bacterial infection, results in
an estimated 200,000–600,000 deaths in the developing
world each year (Sur et al. 2009). Recognition that
expression of the Vi polysaccharide encapsulating S. typhi
is a major determinant of virulence has lead to the devel-
opment of a ViPS vaccine which is marketed in many
developing countries. Recent studies have shown that when
this vaccine was introduced into an area in India where
typhoid fever is endemic, it conferred 61% total protection
in the general population, without evidence of increased
selection of Vi-negative strains or increased antibiotic
resistance (Sur et al. 2009). However, little is known
concerning the genetic and environmental factors that are
associated with ViPS vaccine failure. There is evidence
that ethnicity can play an important role in the immuno-
logical response to certain polysaccharide antigens, and
that genetic factors appear to play a particularly large role
for vaccine-induced antibody responses in young children
(Kimman et al. 2007). Increased knowledge of specific
genetic determinants that impact individual immunological
response to the ViPS vaccine will be important for the
design of next-generation vaccines with even broader
efficacy across diverse populations. In this issue of the
journal, Majumder and colleagues describe their efforts to
identify genetic determinants associated with variability in
antibody response following ViPS vaccination in 984
Indian individuals resident in an area high-risk for typhoid
fever (Majumder et al. 2010). This study represents one of
the first efforts to identify specific genetic factors respon-
sible differential immune response to a polysaccharide
vaccine, and it provides instructive lessons for future
research in this area.
VIPS-specific antibody levels were measured in each
individual pre- and 28 days post-vaccination, and the dif-
ference in specific-antibody response (AR) was quantified.
Large individual differences in the levels of pre- and post
vaccination ViPS specific- antibody were observed, but
there was a very low correlation between the pre- and post
vaccination antibody levels in any given individual. Dif-
ferences in AR could not be explained by variation in age,
gender, or religion. Values of AR were log-transformed to
obtain a normal frequency distribution. A candidate gene
association study was then performed to identify genetic
variants associated with logAR, using 469 independent
common SNPs with minimal linkage disequilibrium and
representing 282 genes present in immunological path-
ways. It is well accepted that any result from such a can-
didate gene association study requires independent
replication, preferably involving multiple different ethic
groups. In this case, no additional independent population
was available for study, so the authors employed a ‘‘non-
standard’’ internal cross-validation design employing cor-
relation of SNP minor allele frequencies with logAR mean
values distributed into pentile groups. The 984 vaccinees
were randomly split into two half-samples of approxi-
mately 500 individuals each, with the first half-sample used
to identify 54 SNPs in 43 genes significantly associated
with variation in immune response, and the second-half
sample used to demonstrate significant replication of 8 of
these SNPs in 7 genes. All eight significant SNPs are
intronic. For six of the eight significant SNPs, an increase
in the minor allele frequency with associated with an
increased antibody response, while for two of the signifi-
cant SNPs, increasing the minor allele frequency was
associated with a decreased antibody response. Each of
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these eight SNPs was also shown to be significantly asso-
ciated with antibody response using PLINK and a more
standard quantitative trait association analysis employing
the entire data set. A haplotype analysis identified an
additional 8 SNPs which were associated with log AR. The
seven genes containing significantly associated SNPs are
known to be involved in polysaccharide recognition, signal
transduction, inhibition of T-cell proliferation, and pro-
inflammatory signaling.
What are the lessons we can learn from this study? The
first is that each significantly associated common SNP had
a very small effect on the overall antibody response fol-
lowing vaccination. Similar observations now seem to be
the rule, rather than the exception, for a wide range of
complex phenotypes investigated using genome wide
association analysis. For phenotypes where tens of thou-
sands of study subjects are available, it is possible to obtain
highly significant associations replicated in multiple pop-
ulations for common variants with a very small genetic
effect. But what about phenotypes such as the one studied
by Majumder et al. (2010), where obtaining a single pop-
ulation sample of a thousand individuals is a tremendous
feat in itself? It will often be necessary to employ ‘‘non-
standard’’ but statistically rigorous approaches, as in the
present study, to identify small genetic signals, which will
often be of marginal statistical significance. The true value
of such results lies not in the size of the p value, but in the
ability to use the results to generate meaningful hypotheses
and experiments to determine the biological basis of the
differences in antibody response. Only with this type of
biological understanding in hand will the ultimate goal of
designing more effective vaccines be realized. The second
lesson learned is that in studies involving clinical out-
comes, where each sample is precious and difficult to come
by, we should make every effort obtain as much detailed
phenotypic information as possible from each subject.
While the present study demonstrates marked variability in
antibody response to vaccination, similar studies with other
polysaccharide vaccines have found that the ability of an
individual to mature antibody avidity, rather than simply
respond with a quantitative increase in antibody, is very
important for vaccine efficacy (Lee et al. 2008). It would
have been interesting to know if subjects in this study show
differences in antibody avidity, and if so, if there were any
genetic correlates associated with this trait. Finally, and
perhaps most importantly, the present study reveals how
important it is to address basic research questions dealing
with rare clinical outcomes in the context of ongoing
clinical trials. A recent study assessing the Vi typhoid
vaccine efficacy in India involved 37,673 study subjects
and found only 34 individuals in the Vi vaccine group who
developed typhoid fever despite Vi vaccination, compared
to 96 subjects who developed typhoid fever in the control
group (Sur et al. 2009). The ability to assess these indi-
viduals for differences in immunological response would
be invaluable as a complement to the present study. It is
impossible to identify such individuals outside the context
of a clinical trial.
Development of next-generation vaccines that have high
levels of efficacy in diverse populations residing in devel-
oping countries is a huge challenge. Pioneering efforts, as
illustrated by the work of Majumder et al. (2010) are
definitely a step in the right direction.
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